DGAP-Adhoc

GSK and Genmab Announce Submission to US Regulatory Authorities for Arzerra(r) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL) - Seite 3

suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab's most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab(r); the
Y-shaped Genmab logo(r); Genmab in combination with the Y-shaped Genmab logo(TM);
the DuoBody(tm) logo; HuMax(r); HuMax-CD20(r); DuoBody(r), HexaBody(TM) and UniBody(r).
Arzerra(r) is a registered trademark of GlaxoSmithKline.

Cautionary statement regarding forward-looking statements for GSK
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Factors that may affect GSK' s operations are described under Item
3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2012.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS

1American Cancer Society, Estimated Number of New Cancer Cases and Deaths by
Sex, US, 2013,
http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/docu
ment/acspc-037124.pdf,
accessed September 18, 2013.
2Teeling et al, J Immunol 2006; 177:362-371

Company Announcement no. 44
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

Click on, or paste the following link into your web browser, to view the associated documents

https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=447446

News Source: NASDAQ OMX



18.10.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Genmab A/S


Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:

End of Announcement DGAP News-Service

---------------------------------------------------------------------------